Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
November 2020
-
Predictive analytics could bring medicines to patients faster
Novartis researchers are using data to accelerate drug development.
-
Featured NewsAchieving 100% renewable electricity
Five virtual power purchase agreements with three developers expected to add more than 275 megawatts of clean power to the electrical grid.
-
Media ReleaseNovartis set to achieve 100% renewable electricity in its European operationsFive virtual power purchase agreements (VPPAs) with three developers expected to add more than 275 megawatts of clean power to the electrical gridProjects expected to address Novartis greenhouse gas…
-
Making Possible: Stepping toward a future with cell and gene therapy
These stories offer a glimpse into the lives of people touched by a new era of medicine.
-
Featured NewsLeading performance in sustainability
Novartis included in Dow Jones Sustainability World Index, with industry-leading performance in environmental and social reporting and human capital.
-
Media ReleaseResults from real-world data and post-hoc analysis of Novartis Beovu® pivotal trials presented at AAO 2020Initial findings on patient characteristics and event likelihood provide insights related to Beovu use in wet AMD1,2 Follows establishment of multi-disciplinary expert coalition and Novartis…
-
Media ReleaseNew Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and genderPooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female…
-
Featured NewsStudy suggests there may be two stages of fatal lung disease in COVID-19
NIBR translational immunologists and academic colleagues observe two distinct molecular patterns of disease progression in lung tissue samples.
-
Media ReleaseNovartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)The Phase III trial investigating canakinumab plus standard of care (SoC) did not meet its primary endpoint of a greater chance of patient survival without the need for invasive mechanical…
-
Media ReleaseNovartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind studySignificant reduction of synovitis (joint lining inflammation) was demonstrated with Cosentyx® at Week 12 vs. placebo, with improvements as early as Week 11 ULTIMATE is the first…
-
Need for new heart disease medicines drives wave of potential therapies
Novartis is investing in a novel type of medicine to reduce the risk of heart disease.
-
Media ReleaseNovartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine preventionThe first randomized, double blind, head-to-head study of Aimovig® (erenumab) against topiramate in patients with episodic and chronic migraine (HER-MES) achieved superiority in its primary and…
Pagination
- ‹ Previous page
- 1
- …
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- …
- 152
- › Next page